Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...
Mens Zealand Pharma kan hæve armene, må stemningen være mere trykket i Bagsværd, hvor Novo Nordisk har hovedkontor. Danmarks suverænt største virksomheder er ...
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
Danmarks mest værdifulde virksomhed, Novo Nordisk, har fået skåret omkring en tiendedel af sin værdi væk i løbet af dagen. I ...
Studie af Novos nye fedme-blockbuster viser 'overlegen effektivitet' - alligevel falder aktien massivt Danmarks mest ...
Aktiekursen for Novo Nordisk er øjeblikkeligt begyndt at falde, efter at den danske medicinalgigant har offentliggjort nye ...
Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen ...
BAGSVAERD, Denmark I March 10, 2025 I Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme.
One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...
Novo Nordisk, headquartered in Bagsvaerd, Denmark, is a global healthcare company with more than 90 years in diabetes care and additional experience in developing treatments for other serious chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results